Blue Sky Alternative Investments has rejected US hedge fund Glaucus' short thesis on the stock as being riddled with falsehoods after Glaucus claimed the homegrown asset manager's shares were 77 per cent over-valued.
Vesna Poljak is the Companies editor. She was previously the Markets editor with a special interest in the investment industry, hedge funds and accounting. She is based in the Sydney newsroom. Connect with Vesna on Twitter. Email Vesna at vpoljak@afr.com
Jonathan Shapiro writes about banking and finance, specialising in hedge funds, corporate debt, private equity and investment banking. He is based in Sydney. Connect with Jonathan on Twitter. Email Jonathan at jonathan.shapiro@afr.com
